We look forward to a strong partnership that we believe can have meaningful impact." Second Quarter 2020 and Recent Highlights XHANCE Prescriptions The number of XHANCE ® (fluticasone propionate) prescriptions increased by 84% from second quarter 2019 to second quarter 2020. Kaléo Co-Promotion Agreement In July the Company announced the signing of an agreement with kaléo, a pharmaceutical company dedicated to building innovative solutions for serious and life-threatening medical conditions, to co-promote XHANCE. Under the terms of the agreement, kaléo will promote XHANCE to an agreed-upon audience of office-based healthcare professionals, which is expected to increase promotional reach and frequency starting by the fourth quarter of 2020. The audience includes nearly 6,000 prescribers about half of whom are outside of the current Optinose called-on universe of approximately 10,000 healthcare professionals.